武汉地区34家医院2011-2013年抗病毒药物应用分析

Utilization Analysis of Antiviral Drugs of 34 Hospitals in Wuhan Area from 2011 to 2013

目的:为临床合理使用抗病毒药物提供参考。方法:采用回顾性方法,对武汉地区2011-2013年34家医院抗病毒药物的销售金额、用药频度(DDDs)和日均费用(DDC)进行统计和分析。结果:2011-2013年间武汉地区多数抗病毒药物年销售金额和DDDs逐年上升。销售金额稳居前5位的是恩替卡韦、阿德福韦酯、拉米夫定、替比夫定、更昔洛韦;DDDs稳居前5位的为阿德福韦酯、恩替卡韦、替比夫定、拉米夫定、三氮唑核苷,其中恩替卡韦销售金额在2013年占比最高,达43.33%,且其DDDs增长最快。奥司他韦2013年销售金额猛增,约为2012年的18倍,其DDDs亦增长迅速;而穿琥宁的销售金额、DDDs明显下降。多数药物的DDC趋于稳定,但穿琥宁和奥司他韦的DDC波动较大。结论:武汉地区2011-2013年抗病毒药物的使用相对稳定,抗肝炎病毒的核苷类等西药占据抗病毒药主要市场。恩替卡韦的销售金额和DDDs增长迅速,而穿琥宁注射液的应用明显下降。

OBJECTIVE： To provide reference for the rational use of antiviral drugs in the clinic. METHODS： The sales amount, DDDs and DDC of antiviral drugs of 34 hospitals in Wuhan from 2011 to 2013 were statistically analyzed by retrospective method. RESULTS： The sales amount and DDDs of most antiviral drugs in Wuhan area from 2011 to 2013 were increased year by year. Entecavir, adefovir, lamivudine, telbivudine and ganciclovir ranked the top 5 in terms of sales amount, and adefovir, enteca- vir, telbivudine, lamivudine and ribavirin ranked the top 5 in terms of DDDs, among which, entecavir （43.33%） had the highest proportion in sales amount in 2013 and its DDDs had the fastest increasing. Sales amount of oseltamivir in 2013 was about 18 times that of 2012, and its DDDs were also increasing rapidly; however, sales amount and DDDs of Chuanhuning were obviously de- creased. The DDC of most drugs was relatively stable, however, the DDC of oseltamivir and Chuanhuning had large fluctuation. CONCLUSIONS： The utilization of antiviral drugs in Wuhan area from 2011 to 2013 is basically stable, western medicineas antihepatiti virus nucleoside took up main antiviral drug market. The sales amount and DDDs of entecavir increases rapidly and the utilization of Chuanhuning injection is obviously decreased.